Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis (R01 Clinical Trial Not Allowed)
ID: 359021Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359021
Timeline
    Description

    The National Institutes of Health (NIH) is offering a grant opportunity titled "Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis (R01 Clinical Trial Not Allowed)." This initiative aims to solicit research applications focused on the preclinical development of lead candidate vaccines to combat Mycobacterium tuberculosis (Mtb) infection and disease, thereby enhancing the clinical pipeline of viable vaccine candidates. The program is critical for advancing public health efforts against tuberculosis, a significant global health challenge. The estimated total funding for this program is $4,730,000, with approximately five awards expected. Interested applicants can reach out to Katrin Eichelberg, MSc, PhD, at keichelberg@nih.gov or call 240-669-2921 for further information. Key deadlines include an estimated synopsis post date of September 8, 2025, and a close date of November 7, 2025, with awards anticipated to be made by July 1, 2026.

    Point(s) of Contact
    Katrin Eichelberg, MSc, PhD National Institute of Allergy and Infectious Diseases (NIAID)
    (240) 669-2921
    keichelberg@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Tuberculosis Research Units (P01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the establishment of multidisciplinary Tuberculosis Research Units (TBRUs) through a grant program aimed at enhancing the understanding of Mycobacterium tuberculosis (Mtb) and its interactions with the host. This initiative seeks to foster collaborative research that characterizes the roles of bacterial and host heterogeneity in infection outcomes and disease progression, with a focus on identifying determinants relevant to Mtb establishment and dissemination. The total estimated program funding is $10 million, with approximately five awards expected, and interested applicants are encouraged to begin forming collaborations in anticipation of the Notice of Funding Opportunity (NOFO) expected to be published in September 2025. For further inquiries, potential applicants can contact Richard T. Robinson, Ph.D., at richard.robinson@nih.gov or by phone at 202-607-8565.
    Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB)," aimed at supporting research on the long-term cardiopulmonary effects following tuberculosis (TB) treatment in both adults and children, particularly focusing on individuals with and without HIV. This initiative encourages innovative epidemiological and observational studies to better characterize post-TB lung disease (PTLD) and its associated health impacts, utilizing existing cohorts of TB participants. Interested applicants, including higher education institutions, non-profits, and government entities, must adhere to specific guidelines for submission through the NIH ASSIST system, with applications accepted until May 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Innovation for HIV Vaccine Discovery" (NOFO Number PAR-23-169) aimed at supporting high-risk, high-impact early discovery research focused on innovative vaccine approaches to prevent HIV acquisition and ongoing infection. This initiative emphasizes a Go/No-Go funding approach, requiring applicants to demonstrate measurable progress towards defined goals by the end of Year 2, with continued funding contingent upon meeting these criteria. The overall budget for this initiative is approximately $2 million for fiscal year 2024, with individual project budgets capped at $350,000 per year, and applications must be submitted via Grants.gov by August 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)" aimed at supporting research into the immunometabolic changes induced by HIV that may elevate the risk of tuberculosis (TB) and hepatitis B virus (HBV) in individuals on combination antiretroviral therapy (cART). This initiative seeks to fund investigator-led studies that explore the long-term effects of HIV-related alterations in immune metabolism on disease progression and treatment responses, with a focus on identifying biomarkers and innovative therapies to mitigate these risks. The grant is open to a wide range of eligible applicants, including higher education institutions, non-profits, and for-profit organizations, with no cost-sharing requirements. Interested parties should note that the application submission deadlines range from April 2025 to January 2028, and they can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For further details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-315.html.
    International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative encourages applications from organizations based in low- and lower-middle-income economies, as classified by the World Bank, and seeks innovative proposals addressing diseases such as HIV/AIDS, tuberculosis, and malaria, with a focus on enhancing local scientific capacity. The total funding available for fiscal year 2024 is approximately $1,360,000, with individual project budgets capped at $125,000 per year for a maximum of five years. Interested applicants can find more information and submission guidelines at the NIH website, with applications accepted until August 1, 2025.
    HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "HIV Vaccine Research and Design (HIVRAD) Program," aimed at advancing research for an effective prophylactic vaccine against HIV/AIDS. This grant encourages multi-disciplinary projects that address significant scientific questions in vaccine discovery, including preclinical evaluations in non-human primate models, while explicitly prohibiting clinical trials. The NIH plans to fund 1-2 awards totaling approximately $5 million for fiscal year 2025, with applications due by March 13, 2024, and an open submission date starting February 13, 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application guidelines available at https://grants.nih.gov/grants/guide/pa-files/PAR-24-037.html.
    Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)" aimed at supporting the development of broadly protective vaccines for hepatitis C virus (HCV). This initiative seeks to establish a consortium of Research Centers that will focus on the design, optimization, evaluation, and advancement of vaccine candidates into clinical trials, encouraging collaborative investigations among experts in HCV vaccine development. The estimated total program funding is $8.3 million, with four awards expected, and interested applicants are encouraged to prepare their proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release, which is expected to be published on July 7, 2025. For further inquiries, potential applicants can contact Dr. Rajeev Gautam at rajeev.gautam@nih.gov or by phone at 301-761-5347.
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk," aimed at supporting research into the immunometabolic changes induced by HIV in individuals undergoing combination antiretroviral therapy. This initiative seeks to investigate how these alterations affect immune responses and increase the risk of subsequent infections, specifically tuberculosis (TB) and hepatitis B virus (HBV). The funding opportunity is particularly significant for advancing understanding in the field of HIV-related health risks and aims to foster innovative research approaches, including the use of machine learning and AI to identify biomarkers and therapeutic targets. Eligible applicants can receive up to $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-316.html.
    Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV) program, aimed at advancing research in the field of infectious diseases. This initiative seeks to support innovative research that elucidates mechanisms of persistence and pathogenesis of Hepatitis B, develops clinically relevant biomarkers, identifies new drug targets, and creates non-invasive diagnostics, leveraging existing clinical data and sample repositories. With an estimated total program funding of $8 million and the expectation of awarding two grants, interested small businesses should note that the application process is open, with key deadlines including an estimated synopsis close date of August 19, 2026, and an anticipated award date of March 1, 2027. For further inquiries, applicants can contact Josh Radke, Ph.D., at josh.radke@nih.gov or by phone at 301-761-6525.
    Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Planning for Product Development Strategy," aimed at supporting the development of comprehensive strategies for next-generation treatments and preventive measures for HIV and its associated complications. This grant opportunity encourages eligible applicants, including various educational institutions and community organizations, to create innovative product development plans that align with FDA guidelines, facilitating the submission of Investigational New Drug (IND) applications. With a total estimated funding of $225,000 available for individual projects, applications are due by December 5, 2026, and must adhere to specific guidelines emphasizing scientific merit and compliance. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link provided in the announcement.